title: Labdane diterpenes protect against anoxia/reperfusion injury in cardiomyocytes: involvement of AKT activation.
abstract: Several labdane diterpenes exert anti-inflammatory and cytoprotective actions; therefore, we have investigated whether these molecules protect cardiomyocytes in an anoxia/reperfusion (A/R) model, establishing the molecular mechanisms involved in the process. The cardioprotective activity of three diterpenes (T1, T2 and T3) was studied in the H9c2 cell line and in isolated rat cardiomyocyte subjected to A/R injury. In both cases, treatment with diterpenes T1 and T2 protected from A/R-induced apoptosis, as deduced by a decrease in the percentage of apoptotic and caspase-3 active positive cells, a decrease in the Bcl-2/Bax ratio and an increase in the expression of antiapoptotic proteins. Analysis of cell survival signaling pathways showed that diterpenes T1 and T2 added after A/R increased phospho-AKT and phospho-ERK 1/2 levels. These cardioprotective effects were lost when AKT activity was pharmacologically inhibited. Moreover, the labdane-induced cardioprotection involves activation of AMPK, suggesting a role for energy homeostasis in their mechanism of action. Labdane diterpenes (T1 and T2) also exerted cardioprotective effects against A/R-induced injury in isolated cardiomyocytes and the mechanisms involved activation of specific survival signals (PI3K/AKT pathways, ERK1/2 and AMPK) and inhibition of apoptosis.
authors.affiliation: Departamento de Farmacología, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Cuadrado
authors.forename: M
authors.initials: M
authors.lastname: Fernández-Velasco
authors.forename: L
authors.initials: L
authors.lastname: Boscá
authors.forename: B
authors.initials: B
authors.lastname: de Las Heras
mesh_terms: D000818:Animals; D015687:Cell Hypoxia / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004224:Diterpenes / Q000494:pharmacology*; D004789:Enzyme Activation / Q000187:drug effects; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000378:metabolism / Q000517:prevention & control*; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction / Q000187:drug effects; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: D004224:Diterpenes; D051028:bcl-2-Associated X Protein; D051057:Proto-Oncogene Proteins c-akt; D048049:Extracellular Signal-Regulated MAP Kinases
references.citation: Rev Esp Cardiol. 2009 Feb;62(2):199-209
references.pmid: 19232193
references.citation: Toxicol Appl Pharmacol. 2008 Apr 15;228(2):179-89
references.pmid: 18190942
references.citation: J Immunol Methods. 1983 Dec 16;65(1-2):55-63
references.pmid: 6606682
references.citation: Br J Pharmacol. 2007 Sep;152(2):249-55
references.pmid: 17618303
references.citation: Circulation. 2009 Feb 17;119(6):835-44
references.pmid: 19188503
references.citation: Nat Prod Rep. 2011 Mar;28(3):529-42
references.pmid: 21225077
references.citation: Circulation. 2001 Jul 17;104(3):330-5
references.pmid: 11457753
references.citation: Life Sci. 2011 Apr 11;88(15-16):725-9
references.pmid: 21338613
references.citation: Cardiovasc Res. 2006 Oct 1;72(1):152-62
references.pmid: 16901477
references.citation: Atherosclerosis. 2009 Jun;204(2):334-41
references.pmid: 19081095
references.citation: Cardiovasc Res. 2010 Apr 1;86(1):103-12
references.pmid: 19959541
references.citation: Circulation. 2005 Aug 30;112(9 Suppl):I117-22
references.pmid: 16159802
references.citation: Br J Pharmacol. 1999 Oct;128(3):605-12
references.pmid: 10516639
references.citation: Curr Med Chem. 2005;12(11):1295-317
references.pmid: 15974998
references.citation: Curr Pharm Biotechnol. 2010 Dec;11(8):868-74
references.pmid: 20874692
references.citation: J Biol Chem. 2001 May 11;276(19):15854-60
references.pmid: 11278990
references.citation: Circ Res. 2007 Mar 30;100(6):914-22
references.pmid: 17332429
references.citation: J Mol Cell Cardiol. 2005 Apr;38(4):617-23
references.pmid: 15808838
references.citation: J Physiol. 2003 Dec 1;553(Pt 2):395-405
references.pmid: 14514868
references.citation: Autophagy. 2007 Jul-Aug;3(4):405-7
references.pmid: 17471015
references.citation: Am J Cardiol. 2010 Aug 1;106(3):360-8
references.pmid: 20643246
references.citation: J Clin Invest. 2009 Dec;119(12):3807-16
references.pmid: 19920350
references.citation: Eur J Pharmacol. 2010 Dec 15;649(1-3):100-7
references.pmid: 20863824
references.citation: Cardiovasc Pathol. 2005 Jul-Aug;14(4):170-5
references.pmid: 16009313
references.citation: Circ Res. 2011 Apr 29;108(9):1133-45
references.pmid: 21527743
references.citation: Circ J. 2009 Jul;73(7):1171-7
references.pmid: 19506318
references.citation: Curr Pharm Des. 2011;17(20):2017-35
references.pmid: 21718247
references.citation: FASEB J. 2004 Oct;18(13):1621-3
references.pmid: 15319365
references.citation: Inflamm Allergy Drug Targets. 2009 Mar;8(1):28-39
references.pmid: 19275691
references.citation: Circ Res. 1996 Nov;79(5):949-56
references.pmid: 8888687
references.citation: Curr Pharm Des. 2011;17(18):1783-93
references.pmid: 21631422
references.citation: Nat Rev Cardiol. 2011 Jun 21;8(11):619-29
references.pmid: 21691310
references.citation: Eur J Pharmacol. 2011 May 11;658(2-3):160-7
references.pmid: 21371449
references.citation: J Clin Invest. 2004 Aug;114(4):495-503
references.pmid: 15314686
references.citation: Expert Rev Cardiovasc Ther. 2007 Nov;5(6):1123-34
references.pmid: 18035928
references.citation: Circulation. 2007 Sep 18;116(12):1413-23
references.pmid: 17875982
references.citation: Z Naturforsch C J Biosci. 1997 Nov-Dec;52(11-12):844-9
references.pmid: 9463942
references.citation: Cardiovasc Res. 2004 Feb 15;61(3):448-60
references.pmid: 14962476